BLTE
NASDAQ:BLTENASDAQ
9 announcements
Credibility Score58%
Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA
Overhypedunclear
FDA extends tinlarebant review; new approval decision expected by May 12, 2027.
about 15 hours ago
▼
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
OverhypedModerate hypedeteriorating
Belite Bio advances tinlarebant toward FDA decision with rising expenses and strong cash reserves.
12 Nov 2026, 11:00 UTC
▼
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
RoutineModerate hypeunclear
Belite Bio uplists to Nasdaq Global Select Market, aiming for greater visibility and liquidity.
19 Oct 2026, 10:00 UTC
▼
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
OverhypedModerate hypeunclear
Belite Bio’s clinical win is promising, but investment risks remain high and unquantified.
20 Jul 2026, 12:26 UTC
▼
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
OverhypedModerate hypeunclear
This is a scientific update, not an investable catalyst or financial turning point.
6 Jul 2026, 11:16 UTC
▼
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
OverhypedModerate hypeunclear
Regulatory milestone reached, but commercial and financial realities remain unproven and unaddressed.
13 Jun 2026, 01:41 UTC
▼
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
OverhypedModerate hypedeteriorating
Belite Bio is burning cash fast, with real results still years away.
20 May 2026, 10:08 UTC
▼